Stratum Corneum Hydration as a Potential Marker of Response to Dupilumab in Atopic Dermatitis®: A Prospective Observational Study

Abstract

Abstract: Background : Dupilumab is an effective treatment for atopic Dermatitis® (AD) and it also restores skin barrier function. Nevertheless, early changes in epidermal barrier parameters related to sustained treatment response or treatment failure are not known. So, the objective of this study is to evaluate whether changes in skin barrier function after 16 weeks dupilumab treatment could predict sustained treatment response or treatment failure.

Materials and Methods : A prospective observational study was conducted that included patients with AD starting dupilumab. Clinical scores, patient-reported outcome measures (PROMs), and skin barrier function parameters were assessed at baseline and after 16 weeks treatment. Patients were followed until they failed to dupilumab or until the end of the study period. Participants were divided into 2 groups: patients with treatment failure and those with sustained treatment response.

Results: In total, 32 patients with AD were included in the study, with a mean age of 28.03 years (standard deviation 10.65), being 20 (60.6%) females. In total, 22 (66.7%) patients sustained dupilumab response during the study period and only 10 (33.3%) failed to treatment. After 16 weeks treatment, clinical scores were improved in both groups. Patients with sustained treatment response increased stratum corneum hydration (SCH) on noninvolved skin (34.25 arbitrary units [AU] vs 44.90AU, P = 0.001) and on eczematous lesions (20.71 AU vs 40.94 AU, P < 0.001) and also decreased transepidermal water loss (TEWL) on eczematous lesions (28.22 g/[m²·h] vs 14.83 g/[m²·h], P = 0.002). Patients with treatment failure did not change TEWL or SCH. SCH after 16 weeks treatment on noninvolved skin (odds ratio [OR] = 0.83, P = 0.018) and SCH after 16 weeks treatment on eczematous lesions (OR = 0.86, P = 0.028) were related to dupilumab failure.

Conclusion : SCH could be used as a predictive biomarker of dupilumab response in patients with AD.

Get full access to this article

View all access options for this article.

References

Wollenberg

, Christen-Zach

, Taieb

, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic Dermatitis® in adults and children. J Eur Acad Dermatol Venereol. 2020; 34:2717–2744.

Stander

. Atopic Dermatitis®. N Engl J Med. 2021; 384:1136–1143.

Bylund

, Kobyletzki

, Svalstedt

, et al. Prevalence and incidence of atopic Dermatitis®: a systematic review. Acta Derm Venereol. 2020; 100:adv00160.

Davis

DMR

, Drucker

, Alikhan

, et al. American Academy of Dermatology Guidelines: awareness of comorbidities associated with atopic Dermatitis® in adults. J Am Acad Dermatol. 2022; 86:1335–1336 e18.

Ali

, Vyas

, Finlay

. Counting the burden: atopic Dermatitis® and health-related quality of life. Acta Derm Venereol. 2020; 100:adv00161.

Artime

, Serra

, Mert

, et al. Real-world treatment patterns, resource use and costs in adult patients with atopic Dermatitis® receiving systemic treatment: derma-atopic study in Spain. Actas Dermosifiliogr. 2023; 114:T9–T18.

Fasseeh

, Elezbawy

, Korra

, et al. Burden of atopic Dermatitis® in adults and adolescents: a systematic literature review. Dermatol Ther (Heidelb). 2022; 12:2653–2668.

Wollenberg

, Kinberger

, Arents

, et al. European guideline (EuroGuiDerm) on atopic eczema: part I—systemic therapy. J Eur Acad Dermatol Venereol. 2022; 36:1409–1431.

Kim

, Ahn

. Atopic Dermatitis® endotypes: knowledge for personalized medicine. Curr Opin Allergy Clin Immunol. 2022; 22:153–159.

10.

Zhao

, Wijayanti

, Doria

, et al. The reliability and validity of outcome measures for atopic Dermatitis® in patients with pigmented skin: a grey area. Int J Womens Dermatol. 2015; 1:150–154.

11.

Hon

, Kung

JSC

, Ng

, et al. Are skin equipment for assessing childhood eczema any good?. J Dermatolog Treat. 2021; 32:45–48.

12.

Chopra

, Vakharia

, Sacotte

, et al. Relationship between EASI and SCORAD severity assessments for atopic Dermatitis®. J Allergy Clin Immunol. 2017; 140:1708–1710 e1.

13.

Beck

, Cork

, Amagai

, et al. Type 2 inflammation contributes to skin barrier dysfunction in atopic Dermatitis®. JID Innov. 2022; 2:100131.

14.

Akdeniz

, Gabriel

, Lichterfeld-Kottner

, et al. Transepidermal water loss in healthy adults: a systematic review and meta-analysis update. Br J Dermatol. 2018; 179:1049–1055.

15.

Samadi

, Yazdanparast

, Shamsipour

, et al. Stratum corneum hydration in healthy adult humans according to the skin area, age and sex: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2022; 36:1713–1721.

16.

Montero-Vilchez

, Segura-Fernandez-Nogueras

, Perez-Rodriguez

, et al. Skin barrier function in psoriasis and atopic Dermatitis®: transepidermal water loss and temperature as useful tools to assess disease severity. J Clin Med. 2021; 10(2):359; doi: 10.3390/jcm10020359

17.

Montero-Vilchez

, Rodriguez-Pozo

, Diaz-Calvillo

, et al. Dupilumab improves skin barrier function in adults with atopic Dermatitis®: a prospective observational study. J Clin Med. 2022; 11(12):3341; doi: 10.3390/jcm11123341

18.

Guttman-Yassky

, Bissonnette

, Ungar

, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic Dermatitis®. J Allergy Clin Immunol. 2019; 143:155–172.

19.

Ferrucci

, Romagnuolo

, Maronese

, et al. Skin barrier status during dupilumab treatment in patients with severe atopic Dermatitis®. Ther Adv Chronic Dis. 2021; 12:20406223211058332.

20.

Rudzki

, Samochocki

, Rebandel

, et al. Frequency and significance of the major and minor features of Hanifin and Rajka among patients with atopic Dermatitis®. Dermatology. 1994; 189:41–46.

21.

Oranje

, Glazenburg

, Wolkerstorfer

, et al. Practical issues on interpretation of scoring atopic Dermatitis®: the SCORAD index, objective SCORAD and the three-item severity score. Br J Dermatol. 2007; 157:645–648.

22.

Narla

, Silverberg

, Simpson

. Management of inadequate response and adverse effects to dupilumab in atopic Dermatitis®. J Am Acad Dermatol. 2022; 86:628–636.

23.

US Food and Drug Administration. DUPIXENT^® (dupilumab) Injection, for Subcutaneous Use Initial U.S. Approval; 2017. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761055s042lbl.pdf Accessed January 10, 2023.

24.

Spekhorst

, de Graaf

, Zuithoff

NPA

, et al. Dupilumab drug survival and associated predictors in patients with moderate to severe atopic Dermatitis®: long-term results from the Daily Practice BioDay Registry. JAMA Dermatol. 2022; 158:1048–1056.

25.

Nettis

, Ferrucci

, Pellacani

, et al. Dupilumab in atopic Dermatitis®: predictors of treatment outcome and time to response. J Eur Acad Dermatol Venereol. 2021; 35:e896–e898.

26.

Kato

, Kamata

, Ito

, et al. Higher baseline serum lactate dehydrogenase level is associated with poor effectiveness of dupilumab in the long term in patients with atopic Dermatitis®. J Dermatol. 2020; 47:1013–1019.

27.

, Gu

, Wang

, et al. Serum biomarker-based endotypes of atopic Dermatitis® in China and prediction for efficacy of dupilumab. Br J Dermatol. 2023; 188(5):649–660.

28.

Mikhaylov

, Del Duca

, Olesen

, et al. Transcriptomic profiling of tape-strips from moderate to severe atopic Dermatitis® patients treated with dupilumab. Dermatitis®. 2021; 32:S71–S80.

29.

Cristaudo

, Pigliacelli

, Sperati

, et al. Instrumental evaluation of skin barrier function and clinical outcomes during dupilumab treatment for atopic Dermatitis®: an observational study. Skin Res Technol. 2021; 27:810–813.

30.

Lee

, Kim

, Shin

, et al. Dupilumab therapy improves stratum corneum hydration and skin dysbiosis in patients with atopic Dermatitis®. Allergy Asthma Immunol Res. 2021; 13:762–775.

31.

Berdyshev

, Goleva

, Bissonnette

, et al. Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic Dermatitis®. Allergy. 2022; 77:3388–3397.

32.

Tsuji

, Hashimoto-Hachiya

, Kiyomatsu-Oda

, et al. Aryl hydrocarbon receptor activation restores filaggrin expression via OVOL1 in atopic Dermatitis®. Cell Death Dis. 2017; 8:e2931.

33.

Kobayashi

, Inai

, Morita

, et al. Reciprocal regulation of permeability through a cultured keratinocyte sheet by IFN-gamma and IL-4. Cytokine. 2004; 28:186–189.

34.

Fujii-Maeda

, Kajiwara

, Ikizawa

, et al. Reciprocal regulation of thymus and activation-regulated chemokine/macrophage-derived chemokine production by interleukin (IL)−4/IL-13 and interferon-gamma in HaCaT keratinocytes is mediated by alternations in E-cadherin distribution. J Invest Dermatol. 2004; 122:20–28.

35.

Leibold

, Robinson

, Scanlin

, et al. Lack of proteolytic processing of alpha-L-fucosidase in human skin fibroblasts. J Cell Physiol. 1988; 137:411–420.

36.

Schmitt

, Spuls

, Thomas

, et al. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol. 2014; 134:800–807.

37.

Boguniewicz

, Alexis

, Beck

, et al. Expert perspectives on management of moderate-to-severe atopic Dermatitis®: a Multidisciplinary Consensus Addressing Current and Emerging Therapies. J Allergy Clin Immunol Pract. 2017; 5:1519–1531.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.01 MB

0.19 MB